Why Is Foghorn Therapeutics (FHTX) Stock Down -22.95% Today?
Key Takeaways
- Shares fell roughly 23% to about $2.25 in midday trading, extending a two-day collapse.
- Primary catalyst: a continuing selloff after FHTX and Eli Lilly ended their oncology collaboration and shelved lead candidate FHD-909.
- Secondary driver: a wave of analyst downgrades and price-target cuts hit the stock Friday morning.
- Cost cuts: the company is reducing its workforce by approximately 40% to extend its cash runway.
- Technical pressure: shares are trading near 52-week lows on exceptionally heavy volume.
Opening Summary
Foghorn Therapeutics Inc. (FHTX), a Watertown, Massachusetts-based clinical-stage biotech that develops precision medicines targeting the chromatin regulatory system, saw its stock plunge again in Friday's session. Shares were down approximately 22.95% to around $2.25 as of midday, compared with a prior close of $2.92. The decline extends Thursday's sharp selloff after the company announced it would not advance its lead oncology candidate and that its high-profile partnership with Eli Lilly (LLY) had effectively ended.
Lilly Collaboration Ends, FHD-909 Shelved
The core catalyst is the abrupt end of Foghorn's collaboration with Eli Lilly. After reviewing Phase 1 dose-escalation data, the two companies decided not to advance FHD-909 (LY4050784), a first-in-class selective SMARCA2 inhibitor, into the clinical development expansion phase. The companies also opted not to move forward with a separate selective SMARCA2 degrader program and said they do not anticipate further collaboration activities.
While the drug demonstrated a favorable safety profile and achieved exposures that exceeded preclinical targets, Chief Executive Adrian Gottschalk said the underlying "synthetic lethality" biology "has not translated into the level of efficacy required to further advance the program." For investors, the decision removes the company's most advanced clinical asset and a key source of future milestone payments, fundamentally resetting the pipeline story.
Analyst Downgrades Compound the Selling
The Friday leg lower was amplified by a flurry of analyst actions. Wedbush downgraded the stock to Neutral from Outperform and slashed its price target to $2 from $10, citing the end of the Lilly collaboration as the primary driver of its prior bullish thesis. BTIG and TD Cowen each moved to Neutral/Hold, while Citizens shifted to Market Perform, with one analyst noting the company lacks "near-term catalysts around remaining assets." H.C. Wainwright kept a Buy rating but cut its target to $5 from $13.
The collective message from Wall Street is that Foghorn's valuation now hinges on earlier-stage, wholly owned programs that are years away from clinical proof, leaving limited near-term upside drivers.
Restructuring and 40% Workforce Reduction
Alongside the pipeline reset, Foghorn said its board approved a strategic reprioritization that will eliminate roughly 40% of its workforce, leaving approximately 65 full-time employees. The restructuring is expected to generate about $2.3 million in one-time severance and benefit charges, substantially completed in the fourth quarter of 2026.
The company will redirect resources toward its wholly owned pipeline, including a selective EP300 degrader, an oral immunology and inflammation program, a selective CBP degrader, and its induced proximity platform. Management said the changes should extend its cash runway into the second half of 2029, but investors are weighing that capital discipline against the loss of a marquee partnership.
Market Context and Trading Activity
Trading activity has been extreme. Thursday's session saw more than 8 million shares change hands, versus an average daily volume in the low hundreds of thousands, and the heavy turnover carried into Friday as the stock probed 52-week lows. The move reflects company-specific news rather than broad biotech weakness, with the broader market and most sector peers trading far more modestly.
From a technical standpoint, the stock has broken decisively below prior support levels and is now hovering near multi-year and all-time-low territory, a sign that sellers remain in control as the market digests the loss of the lead program and the corresponding downgrades.
What Comes Next for FHTX
Looking ahead, investors will focus on execution of the company's proprietary pipeline. Foghorn is targeting an Investigational New Drug (IND) application for its selective EP300 degrader in 2027, with an initial focus on multiple myeloma and diffuse large B-cell lymphoma, while IND-enabling studies for its CBP degrader program are also underway. Upcoming quarterly reports will be closely watched for updated cash balances and further color on restructuring costs.
Key risks include the long development timelines for preclinical assets, potential additional funding needs despite the extended runway, and lingering uncertainty around whether the company's remaining programs can generate clinical data compelling enough to rebuild investor confidence. With most sell-side ratings now at Neutral or Hold, sentiment is likely to remain cautious until new data catalysts emerge.
Trending AI Robots
For traders monitoring volatile biotech names like FHTX, Tickeron's Trending AI Robots page highlights AI-driven trading bots that are currently performing well. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this curated section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving users a way to explore systematic approaches to the market. Visit the Trending AI Robots page to see which strategies are gaining traction right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
FHTX's RSI Oscillator stays in oversold zone for 22 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where FHTX advanced for three days, in 237 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
FHTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
FHTX moved below its 50-day moving average on September 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FHTX crossed bearishly below the 50-day moving average on September 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FHTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FHTX entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. FHTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: FHTX's P/B Ratio (2000.000) is very high in comparison to the industry average of (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (7.553) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FHTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement